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Background
Despite 95% coverage via the prevention-of-mother-to-child-transmission (PMTCT) programme, 
14 000 children in South Africa became HIV-infected in 2012.1 There are many reasons for this 
gap in PMTCT efforts. Late maternal diagnosis of HIV, late antenatal antiretroviral therapy 
(ART) initiation, seroconversion in pregnancy, and inadequate adherence to ART during 
gestation singly and collectively increase the risk of transmission. Early initiation of ART in 
the first few weeks of life significantly reduces the HIV-associated morbidity and mortality 
in HIV-infected infants, compared with deferred initiation2,3 and may reduce the latent HIV-1 
reservoir in children.4 Furthermore, a recent South African study documents that 76% of babies 
who would have tested HIV positive via polymerase chain reaction (PCR) by 6 weeks could 
have been diagnosed at birth.5 Therefore, the Western Cape Province (WCP) Department of 
Health adopted new guidelines6 in June 2014 (and the South African Department of Health in 
December 20147) to test ’high-risk’ infants at birth. Infants testing PCR-positive are started on 
ART as soon as possible.
In March 2014, Médecins Sans Frontières, in collaboration with the University of Stellenbosch, 
started a pilot project in a community healthcare centre in Khayelitsha to establish the impact of 
very early infant diagnosis on ART initiation and to establish the feasibility of implementation 
in a primary care setting. To establish routine testing of high-risk HIV-exposed infants at the 
primary care level, the following steps were taken:
• training and mentorship of healthcare staff at the healthcare centre (midwives, nurses, 
doctors, counsellors) on the new guideline recommendations; the identification and 
management of high-risk infants; and the clinical management of ART initiation in a 
newborn
• routine counselling and consent from mothers for birth PCR testing
• initiation of nevirapine (NVP) and zidovudine (AZT) post-exposure prophylaxis on day one 
in high-risk infants
• PCR and confirmatory viral load testing via the routine courier system to the referring 
National Health Laboratory Service (NHLS) laboratory, with results available within 
48 hours
• counselling all mothers regarding the PCR results at 48 hours of life, when the mother and 
infant return to the health centre for routine post natal care:
 if the PCR result is negative, the mother is advised of the necessity to keep the infant in 
care for repeat HIV testing as per WCP guidelines as well as to continue post-exposure 
prophylaxis
 if the infant is HIV positive, the nurse caring for the mother/infant pair provides 
 standardised ART initiation counselling and ensures the infant is seen by a medical officer 
the same day
• initiation of ART on the same day as diagnosis for clinically well infants, according to 
interim infant ART treatment guidelines developed in consultation with infectious 
disease paediatricians, and referral to the district hospital for clinically unwell 
infants
• close follow-up of the infants on ART: weekly until 6 weeks of age and monthly until 
2 years of age, including routine monitoring bloods and a repeat viral load at 4 months 
of age
• monitoring of further HIV test results in HIV-exposed infants testing negative at birth, to 
identify further HIV-positive infants and to assess the coverage of HIV testing per guidelines 
to 18 months of age.
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By the end of December 2014, we had identified 138 
high-risk infants delivered at the primary healthcare 
centre and we tested 132 high-risk infants (95% of high- 
risk infants delivered at the centre had a birth PCR) of 
whom 3 had a positive HIV PCR. The 3 cases are summarised 
in Table 1 and the lessons learnt from them are described 
below.
Cases of positive HIV polymerase 
chain reaction: Lessons learnt
Case 1
Case 1 was complicated by a mother struggling with 
numerous psychosocial difficulties: low socioeconomic 
status, fear of stigmatisation and of disclosure to her 
partner/family, and deep mistrust of the healthcare 
system. Despite repeated attempts to contact her, she only 
returned to care when the infant was 9 days old after her 
perception of her baby being healthy changed after the infant 
developed conjunctivitis. This case was a good illustration 
of how barriers at the individual level (low socioeconomic 
background and psychological factors such as fear of 
disclosure and stigma) can prevent access to ART for the 
infant.8 By addressing these barriers through individual 
counselling by healthcare providers and peer support from 
an organisation experienced in supporting HIV-positive 
mothers, the mother and infant returned to care and have 
remained in care to date (10 months later). They are both 
showing good adherence and viral suppression.
Case 2
Case 2 confirmed the higher risk of transmission with 
a presumed HIV incident infection in the mother, as 
reported in other studies such as that by Drake et al.9 
Good support and counselling allowed the mother to 
overcome her initial shock and to accept the need to initiate 
her infant on ART. She and her baby are suppressed and 
doing very well.
TABLE 1: Demographics and early outcomes of three HIV-positive infants diagnosed at birth in a primary care setting.
Demographics and outcomes Case 1 Case 2 Case 3
Antenatal risk factors for transmission Mother unbooked in labour (mother  
known ART treatment interrupter)
ART < 12 weeks in pregnancy (late  
booking at 25 weeks [HIV negative]  
and seroconverted at 32 weeks)
ART < 12 weeks in pregnancy (late  
booking at 31 weeks)
- - Mother is a treatment interrupter
- - Infant born prematurely at 36 weeks’ 
gestation
Mother’s results Viral load (2 weeks after delivery): 484 Viral load (2 weeks after delivery): 302 Viral load not available
CD4 162 on day of delivery CD4 281 at 32 weeks CD4 293 at booking at 31 weeks
Time from birth to ART initiation 16 days 2.5 days 2 days
WHO stage at initiation Stage 2 Stage 1 Stage 1
Challenges at initiation Fear of disclosure and stigma Low socio-economic status Low socio-economic status
Distrust of healthcare system Financially dependent on partner No stable relationship
Poor social support - -
Low socio-economic status - -
Financially dependent on partner - -
At ART initiation
Viral load (copies/mL) 871 740 1015 Lower than detectable (LDL) (repeat at  
10 days of life-on ART: 265)
CD4 cell count (percentage of total 
lymphocytes)
1731 (34%) 2082 (27%) 1364 (66%)
HIV drug resistance testing No resistance Amplification not possible owing to low  
viral load
Amplification not possible owing to low 
viral load
Feeding method Formula feeding Reverted to breast feeding when infant 
initiated ART
Reverted to breast feeding when infant 
initiated ART
First ART regimen AZT/3TC/NVP AZT/3TC/NVP AZT/3TC/NVP
Second ART regimen: NVP replaced  
with LPV/r
3 weeks of age (gestational age  
unknown)
2 weeks of age (gestational age  
unknown)
6 weeks of age (42 weeks’ gestational  
age)
Prophylactic medications Co-trimoxazole (started at 4 weeks  
of age)
Co-trimoxazole (started at 4 weeks  
of age)
Co-trimoxazole (started at 4 weeks  
of age)
Isoniazid (INH) for 6 months - -
Viral load (copies/mL) at 4 months† 1823 < 40 (month 3) < 40
- AZT replaced by ABC AZT replaced by ABC
Viral load (copies/mL) at 8 months < 40 Not available yet Not available yet
AZT replaced by ABC - -
Mother VL 3–4 months after delivery < 40 < 40 < 40
Adverse events Hospitalised for bronchiolitis and to  
exclude TB (owing to presumed TB  
contact). Completed 6 months of INH.
Mild anaemia (Hb 10.4) Hospitalised for initial high ALT at ART 
initiation (probably lab error). Repeat  
was normal.
Other challenges encountered Transient migration to Eastern Cape  
over holiday period
Initial mix-up with ARV dosage despite 
extensive counselling
Mother claimed to be ART naïve at  
booking
- Transient migration to Eastern Cape over 
holiday period
-
†, Viral load recommended at 4 months after ART initiation as per Western Cape Government Department of Health prevention-of-mother-to-child-transmission clinical guidelines update.6
ART, antiretroviral therapy; NVP, nevirapine; AZT, zidovudine; INH, Isoniazid.
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Case 3
Case 3 illustrates the importance of early booking as 
intrauterine HIV transmission to the infant could have been 
prevented if the mother had been diagnosed and started on 
ART earlier in the pregnancy. In this instance, too, extensive 
support and counselling assisted the mother in accepting the 
diagnosis and starting treatment for the infant. Both are now 
virologically suppressed.
So far, we have demonstrated that testing high-risk infants 
at birth is possible in a primary care setting, with 129 out of 
130 mothers eager for their infants to be tested at birth (other 
high-risk infants were not tested for other reasons such as 
already being enrolled in another study, mother missed, etc.). 
Although concerns were expressed by healthcare providers 
and counsellors on the psychosocial readiness of the mothers 
to initiate ART, we found that it was possible and sustainable, 
with structured ART initiation counselling and adherence 
support. ART programmes aimed at the implementation of 
early infant diagnosis strategies should consider modification 
of the existing three pre-ART routine counselling sessions as 
essential, given the timing of ART initiation in newborns and 
the early challenges that both mother and infant are likely to 
experience in the first months on ART.
Prior to starting the pilot study, we had concerns about the 
timing of sample transport from the primary care setting 
to the central laboratory. In fact, the average turnaround 
time for PCR results has been 48 hours, allowing prompt 
initiation of babies on ART after birth. Programmatically, it 
may be more difficult in rural areas, where there may be a 
longer turnaround time to obtain results. Furthermore, in our 
pilot project, about 22% of women did not come back for the 
results of the baby’s birth PCR. Using a point of care (POC) 
PCR machine at birth, with good sensitivity and specificity, 
could reduce the attrition of patients not returning for results 
and improve early management of HIV-exposed infants. 
More research is needed to look into which POC platform 
would be optimal and the feasibility of its use at a primary 
care level.
ART initiation in this pilot project was undertaken by a 
general medical officer in a primary care setting, with the 
telephonic support of infectious disease paediatricians. As 
described in an article by Nuttall10 in the present issue of 
the Southern African Journal of HIV Medicine, initiating ART 
in a neonate is more intricate than for a 6-week-old infant 
in terms of available drugs, dosage and monitoring. An 
initial lack of confidence to initiate neonates on ART was 
observed during the mentorship of primary care medical 
officers, mostly related to lack of experience in calculating 
paediatric dosages and in blood draws in neonates. With 
the guidance of infectious disease paediatricians at our 
tertiary referral centre, we designed an interim guide on 
ART initiation at birth where we attempted to simplify blood 
tests for monitoring and the calculation of dosages. Modelled 
on existing ART drug dosing charts, the guide reduces the 
complexity of neonatal ART initiation and thus increases the 
confidence of clinicians managing well infants on ART at 
primary care level.
In addition to being well received by primary care doctors, 
mentorship on primary care ART initiation for stable infants 
was well received by the local district hospital, as it reduces the 
burden on their overstretched services. Furthermore, from the 
patient’s point of view, previous studies show that accessing 
local clinics rather than distant referral hospitals leads to 
better retention in care,8,11 which is what we experienced on 
the ground, with the above three patients’ mothers being 
compliant with their appointments. The mother builds a 
trusting relationship with one or two health workers, which 
probably additionally promotes her retention in care. As we 
observed, assisting the very vulnerable mother-infant pair 
through the initial phase of ART may greatly assist long-term 
compliance with clinic visits.
The major difficulty encountered with ART initiation was for 
the mother to understand the dosage of syrups appropriately, 
particularly with the high number of changes in the first few 
months of treatment. This finding is corroborated by other 
MSF projects in which paediatric treatment failure has been 
linked directly to under-dosage by the caregiver (internal 
source). To overcome this difficulty, sufficient time must be 
spent counselling the mother on how to administer syrups; 
visual methods on how much of each syrup to give (using 
colour stickers and marked syringes) can be very helpful for 
mothers to understand the measurements. Assigning specific 
responsibility to the pharmacist, counsellor, nurse or doctor 
for this education on medication dosing is crucial for ART 
initiation in neonates to be rolled out effectively in a primary 
care setting.
Finally, whilst following up the birth PCR-negative babies, 
we observed that most women take their infants for a 
‘6-weeks PCR’ but very few of them actually come to clinics 
in the right time frame (6–8 weeks). Most of the ‘6-weeks 
PCR’ tests are done at random times, showing that mothers 
return to clinics when it suits them, not when they are given 
a date. Further studies are needed to evaluate the impact of 
this observation as well as the reasons behind it, and how to 
adapt the existing system to the needs and demands of new 
mothers.
Conclusion
We started a pilot project in a primary care centre in 
Khayelitsha in March 2014 to establish the impact of very 
early infant diagnosis in reducing the age at ART initiation, 
and to investigate the feasibility of implementing both early 
diagnosis and early ART initiation in a primary care setting. 
So far, we have diagnosed 3 HIV-positive infants out of 
129 high-risk HIV-exposed babies tested, and all 3 babies 
were initiated on ART from 2 days to 2.5 weeks after birth. 
They are currently doing well: all 3 infants are adherent 
to their medication and are virologically suppressed on 
ART. Overall, we have established the feasibility of testing 
newborns for HIV at birth and initiating ART in the first days 
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of life in a primary care setting with appropriate mentorship 
of healthcare providers and consistent adherence support 
for mothers. By promoting a decentralised model of early 
infant diagnosis at birth, programmes will ensure access 
to care for some of the most vulnerable patients with HIV 
infection.
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